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The aim of this study has been to investigate the potential of serum biomarkers used in clinical practice (CEA, CYFRA
21–1, SCC) together with the serum epidermal growth factor receptor (EGFR) and its associated ligands (EGF, TGF-α,
HB-EGF) as outcome predictors of non-small cell lung cancer (NSCLC) patients treated with the TKI erlotinib.
The pretreatment levels of these markers were evaluated through immunoassays carried out in 58 patients. The
progression-free survival (PFS) and overall survival (OS) were assessed by the Kaplan-Meier method and differences
between groups were compared by means of the Log-Rank test. Association of risk factors with survival was evaluated
using the univariate and multivariate Cox modelling procedures. Higher CEA (>5 ng/mL) and sEGFR (>56.87 ng/mL)
concentrations associated significantly with a higher overall survival. The pre-treatment sEGFR serum levels constituted
an independent prognostic factor. The EGFR gene mutational status and the sEGFR level combination was the single to
associate significantly with longer progression-free survival periods, in circumstances in which the EGFR gene was mutated
and increased protein serum levels were detected. The overall survival as assessed through a Cox analysis revealed similar
death hazards with respect to low sEGFR levels combined both with non-mutated EGFR genotypes and low CEA
serum levels. Our results suggest that the pre-treatment CEA and sEGFR serum levels may provide a comparable
source of information to that supplied by the EGFR gene mutational status with respect to the prognosis of erlotinib
treated NSCLC patients. A combined sEGFR and CEA level appraisal could be of considerable value to select patients to
undergo EGFR-TKI treatments.
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Non-small cell lung cancer (NSCLC) cases account for
approximately 85% of all the lung cancer instances, with
pulmonary carcinomas representing worldwide the lead-
ing death cause derived from cancer (Jemal et al. 2010).
The uncovering of the epidermal growth factor receptor
(EGFR) responsible for cell proliferation and survival
(Baselga 2002) as being constitutively over-expressed in* Correspondence: elena.yaiza.romero.ventosa2@sergas.es
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reproduction in any medium, provided the origthe majority of these tumour types, prompted the devel-
opment of a number of anti-EGFR agents for NSCLC
treatment. The best known anti-EGFR agents comprise
the EGFR tyrosine kinase inhibitors (TKIs), such as gefi-
tinib or ZD1839 (Iressa®, 2005), else erlotinib or OSI-774
(Tarceva®, 2009), all of these agents functioning through
the inhibition of the EGFR phosphorylation and tyrosine
kinase activities as mediated by competitive binding pro-
cesses (Ciardiello and Tortora 2008).
Initial clinical trials concluded that some clinical and
pathological features (Asian ethnicity, never-smokers, fe-
male gender and adenocarcinoma histology) all benefitedr. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
Table 1 Patient and tumour characteristics
Variables Demographics N %
Sex Male 39 67.2
Female 19 32.8
Age (ys) <60 26 44.8
≥60 32 55.2
Smoking status Never smoker 14 24.1
Active 20 34.5
Ever smoker 24 41.4
Histology Adenocarcinoma 41 70.7
Squamous 6 10.3
Unknown 11 19.0




Performance status 0-1 23 39.7
2-3 5 8.6
Unknown 30 51.7
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therapy (Shepherd et al. 2005; Kim et al. 2008; Cappuzzo
et al. 2007; Tokumo et al. 2005). Nowadays, it has been
clearly established that the EGFR gene mutational status
comprises a powerful predictor of the tumour responses
to EGFR-TKI treatments (Lynch et al. 2004; Janne et al.
2005; Cappuzzo et al. 2005, Takano et al. 2005; Hirsch
et al. 2006; van Zandwijk et al. 2007; Mitsudomi et al.
2010), in consequence being widely used to select pa-
tients likely to respond to the medication. Findings de-
rived from the EURTAC (Rosell et al. 2012) and
OPTIMAL studies (Zhou et al. 2011) have strengthened
the rationale to apply prognostic mutation status check-
ing in the case of NSCLC patients.
Nevertheless, inclusive among EGFR mutated patients,
not all individuals respond to EGFR-TKI treatment in
the same manner, as a result the objective positive re-
sponse to EGFR-TKI treatment has ranged 62% to 75%
(Mitsudomi et al. 2010; Tamura et al. 2008; Maemondo
et al. 2010). On the other hand, no EGFR mutations
were identified in 10-20% of patients with partial re-
sponses to EGFR-TKI application (Pao et al. 2004; Lynch
et al. 2004; Cappuzzo et al. 2005; Bell et al. 2005; Han
et al. 2005). This evidence strongly suggests that other
mechanisms besides of the EGFR mutation status deter-
mine the TKI treatment responsiveness (Chang et al.
2011; Cappuzzo et al. 2005; Engelman et al. 2005). Sev-
eral other predictive biomarkers have also been investi-
gated in relation to NSCLC in order to assess TKI
responsiveness. Cappuzzo et al. (2005) reported on EGFR
amplification and high EGFR protein expression levels as-
sociated to gefitinib responsiveness. Likewise, Takano et al.
(2005) respective to recurrent NSCLC patients and Hirsch
et al. (2006) considering a phase III study of advanced
NSCLC subjects determined that an increased EGFR gene
copy number encompasses a favourable gefitinib sensitivity
marker. In addition, significant ErbB-3 over-expression
levels have also been associated with gefitinib sensitivity
(Engelman et al. 2005).
Furthermore, tumour specimens are required in order
to efficiently select patients based on EGFR mutation
profiles, yet sometimes insufficient primary tumour tis-
sue is available or else circumstances dictate that sam-
ples are difficult to obtain having led to EGFR gene
mutation detection failures (Mitsudomi et al. 2010;
Costa et al. 2007).
In this study we have investigated amongst TKI erloti-
nib treated non-small cell lung cancer (NSCLC) patients
the potential predictive outcome of three clinical prac-
tice applied serum biomarkers (CEA, CYFRA 21–1,
SCC) together with the soluble form of EGFR (sEGFR)
and its constituting ligands: epidermal growth factor
(EGF), transforming growth factor-alpha (TGF-α) and
heparin binding epidermal growth factor (HB-EGF).Results
Patient characteristics
The characteristics of the patients included in this study
are displayed in Table 1. The patients’ mean age
amounted to 60.81 years (ranging 38–86) and the group
consisted mostly of men (67.24%). Never-smokers com-
prised 24.1% of the patients. Regarding histological
types, adenocarcinomas were mainly reported (70.7%)
and most tumours were classified into advanced (20.7%
stage IIIb) and metastatic (67.2% stage IV) states. Per-
formance status (PS) could only be established for half
of the patients: 39.7% encompassed PS 0–1 and 8.6%
manifested PS 2–3.
In relation to the previous treatments, patients who
had received one previous chemotherapy line (48.3%)
had undergone a cisplatin-based doublet chemotherapy
pre-treatment. Patients with two different therapies pre-
vious to the erlotinib treatment initiation (25.9%) had re-
ceived cisplatin-based chemotherapy as the first line
(except for one patient) and different second line therap-
ies: 7 patients platinum, 5 patients taxane and 3 patients
gemcitabine or vinorelbine. A total of three treatments
were administered to only 3.4% of the patients: first and
second lines consisted of platinum derivatives and with re-
gard to the third line one patient had received gemcitabine
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had a patient received more than three treatments whereas
the remaining 12 patients had not received any treatment
before commencing the erlotinib therapy (Table 1).
Serum marker concentrations
Table 2 provides the seven serum marker levels pro-
viding their average levels together with ranges. The
pre-treatment levels of the markers sEGFR, EGF, TGF-α
and HB-EGF displayed Gaussian distributions, whilst the
levels of CEA, CYFRA 21–1 and SCC entailed skewed
distributions.
Treatment outcome
The mean erlotinib treatment duration amounted to
6.37 months (spanning from 1–12.0 months). Overall,
erlotinib treatment was well tolerated by the majority of
the individuals. Following to the erlotinib therapy, clin-
ical responses were assessed giving the following results:
no patients exhibited a complete response (CR) to the
therapy; the disease control rate covered 47.4%, of which
a partial response (PR) was observed in 21.1% of the
patients while a stable disease development (SD) was
witnessed in 26.3%; whereas disease progression (PD)
cases accounted for 52.6% of the patients.
Survival analysis stratified by patient and tumour
characteristics
Patients’ follow-up was performed during a period of
approximately 27 months in order to estimate the
progression-free survival (PFS) along with the overall
survival (OS). During that time period, altogether 51
patients suffered tumour progression of which 48 fi-
nally died as a consequence of the lung cancer. The
median PFS and OS extents equalled respectively 3.1
(IC 95%: 2.2–4) and 6.97 months (IC 95%: 4.56–9.37).
Univariate survival analysis was further carried out in
order to assess influences of gender, age, smoking,
performance status, histology, tumour stage, previous
treatment administration and therapy toxicity on theTable 2 CEA, CYFRA 21–1, SCC, sEGFR, EGF, TGF-α and
HB-EGF serum marker concentrations
Markers (units) Sample (N) Median Range
CEA (ng/mL) 35 12.2 0.6 – 10000.0
CYFRA 21–1 (ng/mL) 35 5.5 1.4 – 231.4
SCC (ng/mL) 35 0.9 0.3 – 18.1
sEGFR (ng/mL) 44 59.05 28.4 – 90.2
EGF (pg/mL) 45 757.4 47.4 – 2425.5
TGF-α (pg/mL) 40 18.4 0.01 – 233.2
HB-EGF (pg/mL) 24 157.6 51.3 – 1032.5PFS and OS occurrences of the NSCLC patients
(Table 3).
Positive smoking histories presented significantly lower
PFS (p = 0.042) for active smokers and a hazard ratio (HR)
value of 2 of suffering disease progression (p = 0.046).
Improved performance status at the beginning of the
erlotinib treatment (p = 0.007) and adenocarcinoma
histology (p = 0.045) were significantly associated to
longer overall survival; however, only a poor perform-
ance status remained a significant death predictor as
detected by the Cox analysis, exhibiting a 3.88 times
higher hazard ratio (p = 0.012).
The erlotinib-derived toxicity encompassed a signifi-
cant prognostic factor with respect to both the
progression-free survival (p < 0.001) and the overall sur-
vival (p = 0.009), although with more remarkable differ-
ences in the case of the overall survival. Risk assessment
confirmed that the toxicity represented a protection fac-
tor, with hazard ratios of 0.44 respective to the
progression-free survival (p = 0.013) and 0.35 regarding
the overall survival (p = 0.031).
Patient survival analysis stratified by tumour markers
Table 4 reports the median progression-free survival (PFS)
and overall survival (OS) periods of those patients having
been classified as holding pre-treatment marker levels
below or above of the defined cut-off levels (see Methods),
in addition to the results derived from the Cox analysis in
order to establish progression and death risks. The patient
or sample number disparities compared to Table 2 are due
to censored or missing data.
Two of the serum markers, namely CEA and sEGFR,
were significantly related to an overall survival (OS) pro-
longation when patients manifested elevated levels. CEA
levels above 5 ng/mL had a median OS of 10.2 months,
superior to the 4.4 months of patients exhibiting inferior
levels (p < 0.001). The Cox analysis established a death
hazard ratio (HR) of 0.23 with respect to patients with
an elevated level of CEA (p = 0.001).
As concerned sEGFR, a cut-off value of 56.87 ng/mL
clearly differentiated among patients expressing lower
levels and experiencing lower median overall survival
periods of 4.2 months in contrast to patients display-
ing levels well above of the cut-off value who pre-
sented median overall survival intervals of 9.5 months
(p = 0.016); progression-free survival differences were
nearly significant (p = 0.051). The Cox analysis re-
vealed that elevated sEGFR levels implied a diminished
death hazard ratio corresponding to 0.43 (p = 0.019).
Relationship between EGFR mutation analysis and
treatment response
Mutation analysis of the EGFR gene TK domain exons
18–21 was carried out on tumour specimens drawn
Table 3 Univariate analysis of the clinical and pathological factors in relation to PFS and OS
Progression-free survival Overall survival Univariate cox analysis
Variables Demographics N Mea (95% CI) pb Mea (95% CI) pb Progression Death
HR 95% CI p HR 95% CI p
Sex Male 19 2.1(0.8 – 9.1) 10.6(7.0 – 14.3) 1.00 1.00
Female 39 0.3(2.2 – 3.4) 0.5 5.4(3.6 – 7.2) 0.383 1.22 0.7 – 2.2 0.501 1.31 0.7 – 2.4 0.385
Age (ys) <60 26 2.6(2.1 – 3.1) 5.2(3.4 – 7.1) 1.00 1.00
≥60 32 4.0(1.8 – 6.1) 0.109 9.7(5.5 – 14) 0.303 0.60 0.4 – 1.1 0.112 0.74 0.4 – 1.3 0.305
Smoking No smoker 14 6.2(0.0 – 12.9) 10.6(3.4 –17.8) 1.00 1.00
Active 44 2.7(2.1 – 3.4) 0.042 5.4(3.6 – 7.2) 0.253 2.00 1.0 – 4.0 0.046 1.5 0.7 – 3.0 0.257
Performance status 0-1 23 2.8(2.2 – 3.5) 6.5(2.6 – 10.4) 1.00 1.00
2-3 5 0.4(0.4 – 0.5) 0.254 0.7(0.1 – 1.4) 0.007 1.77 0.66 – 4.8 0.261 3.88 1.3 – 11.1 0.012
Histology Adenocarcinoma 46 2.8(1.9 – 3.6) 7.7(3.8 – 11.6) 1.00 1.00
Squamous 6 2.7(1.5 – 3.9) 0.267 4.4(2.5 – 6.2) 0.045 1.65 0.68 – 4.0 0.273 2.47 0.99 – 6.2 0.054
Stage I-III 19 2.8(2.2 – 3.5) 10.0(5.4 – 14.6) 1.00 1.00
IV 39 3.3(2.0 – 4.6) 0.545 5.8(2.9 – 8.8) 0.315 1.20 0.66 – 2.2 0.546 1.37 0.7 – 2.5 0.318
Prior treatment No 12 3.1(1.7 – 4.6) 5.0(2.4 – 7.7) 1.00 1.00
Yes 46 2.8(2.0 – 3.7) 0.650 7.4(3.5 – 11.3) 0.386 0.86 0.5 – 1.6 0.651 0.74 0.4 – 1.5 0.389
Toxicity No 7 1.8(1.6 – 2.1) 2.3(1.8 – 2.8) 1.00 1.00
Yes 49 3.8(2.2 – 5.3) <0.001 7.8(4.1 – 11.5) 0.009 0.44 0.21 – 0.93 0.031 0.35 0.15 – 0.8 0.013
Abbreviations: Me Median, HR Hazard Ratio, CI Confidence interval.
aMonths; bp value calculated using the Log-Rank test.
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unspecified mutation type, therefore this individual
was further excluded from the subsequent analyses.
EGFR gene related mutations were detected in 11 out
of the resulting 32 patients (34.4%), while the remainingTable 4 Univariate analysis of the serum marker concentratio
Progression-free survival Overall surv
Markers Levels N Mea (95% CI) pb Mea (95% C
CEA <5 11 2.8(1.9 – 3.7) 4.4(2.7 – 6.1)
≥5 24 2.8(1.2 – 4.3) 0.155 10.2(5.9 – 14
CYFRA 21-1 <3.3 10 3.2(0.0 – 7.8) 15.0(0.0 – 31
≥3.3 25 2.8(2.5 – 3.0) 0.317 6.5(4.3 – 8.6)
SCC <1.5 29 2.8(2.0 – 3.7) 7.7(3.7 – 11.7
≥1.5 6 2.7(2.0 – 3.3) 0.500 6.5(4.7 – 8.3)
sEGFR <56.87 20 2.4(1.9 – 2.9) 4.2(0.6 – 7.8)
≥56.87 24 3.2(0.6 – 5.8) 0.051 9.5(5.3 – 13.6
EGF <713.59 22 3.8(1.9 – 5.6) 7.4(3.2 – 11.6
≥713.59 23 2.6(2.0 – 3.2) 0.405 5.1(4.8 – 5.4)
TGF-α <21.81 24 2.3(1.5 – 3.1) 5.1(1.5 – 8.7)
≥21.81 16 2.8(1.8 – 3.7) 0.570 7.7(3.0 – 12.4
HB-EGF <171 14 2.3(0.6 – 4.0) 5.1(1.5 – 8.6)
≥171 10 3.1(1.5 – 4.7) 0.256 15.0(0.0 – 33
Abbreviations: Me Median, HR Hazard Ratio, CI Confidence interval.
aMonths; bp value calculated using the Log-Rank test.21 individuals held the wild type EGFR genotype. All the
variants detected in this study were located on exons 18,
19 and 21; the most frequent mutation consisted of a de-
letion in exon 19 (del19) affecting a total of 8 individuals
(72.7%), another two cases were detected in exon 21ns in relation to PFS and OS
ival Univariate cox analysis
I) pb Progression Death
HR 95% CI p HR 95% CI p
1.00 1.00
.5) <0.001 0.58 0.3 – 1.2 0.161 0.23 0.9 – 0.6 0.001
.9) 1.00 1.00
0.056 1.51 0.67 – 0.38 0.321 2.34 0.95 – 6.0 0.064
) 1.00 1.00
0.184 1.36 0.55 – 3.36 0.503 1.87 0.73 – 4.76 0.192
1.00 1.00
) 0.016 0.53 0.3 – 1.0 0.055 0.43 0.21 – 0.87 0.019
) 1.00 1.00
0.488 1.30 0.7 – 2.4 0.408 1.26 0.7 – 2.4 0.490
1.00 1.00
) 0.732 0.82 0.4 – 1.6 0.572 0.88 0.42 – 1.85 0.733
1.00 1.00
.0) 0.093 0.60 0.3 – 1.5 0.262 0.42 0.15 – 1.2 0.104
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identified in exon 18 (G719X).
Treatment responsiveness was recorded for 31 patients
out of the 32 EGFR mutational status appraised cases.
Gene mutations were detected in 9 out of 17 (52.9%)
cases presenting partial responses (PR) or stable disease
(SD) states after undergoing erlotinib administration;
however, only 2 mutations were present in the 14
(14.3%) cases of disease progression (PD). Furthermore,
EGFR mutations were not significantly associated with
an improved response (p = 0.057, Fisher’s exact Test).
Patient survival analysis stratified by EGFR mutational
status
Progression-free survival (PFS) and overall survival (OS)
were assessed among the 32 patients characterized by
EGFR mutations. The median PFS corresponded to
3.47 months (95% CI: 2.59 – 4.34) while the median OS
was amounted to 6.53 months (95% CI: 3.99 – 9.07). The
Kaplan-Meier analysis and the Log-Rank test detected that
the EGFR gene mutations conferred significant survival ad-
vantages versus the wild type patients, both with respect to
the PFS (8.6 versus 2.8 months, p = 0.012) and also to the
OS (12.6 versus 5.4 months, p = 0.033). Univariate hazard
ratios of the mutated EGFR genotypes corroborated that
those patients bearing mutations held minor progression
and death probabilities (HR of 0.36 and 0.39, respectively).
Results are displayed in Table 5.
Survival analysis of EGFR mutational status characterized
patients stratified by tumour markers (sEGFR and CEA)
The tumour markers sEGFR and CEA, which had
probed significant survival predictors as identified by the
univariate analysis presented in Table 4, were made use
of to repeat the survival analysis with respect to the
EGFR mutational status characterized patients. As had
occurred when all of the patients had been analysed, nei-
ther the sEGFR nor the CEA tumour markers affected
significantly the progression-free survival (PFS). Despite
of the statistical power loss, higher sEGFR (p = 0.013)Table 5 Univariate analysis of serum markers in patients with
Progression-free survival Overall su
Markers Levels N Mea (95% CI) pb Mea (95%
EGFR mutation 11 8.6 (2.0 – 15.1) 12.6 (4.7 –
Wild type 21 2.8 (2.0 – 3.6) 0.012 5.4 (4.2 – 6
CEA <5 8 3.1 (1.8 – 4.4) 4.2 (2.0 – 6
≥5 12 2.8 (0.0 – 6.5) 0.237 10.2 (5.0 –
sEGFR <56.87 20 2.8 (1.7 – 3.8) 4.2 (1.0 – 7
≥56.87 24 3.8 (0.8 – 6.7) 0.106 9.5 (6.1 – 1
Abbreviations: Me Median, HR Hazard Ratio, CI Confidence interval.
aMonths; bp value calculated using the Log-Rank test.and CEA (p = 0.004) levels were again associated with a
significant overall survival (OS) improvement (Table 5).
Survival medians of mutational status characterized pa-
tients were practically identical to those that had been
obtained for all of the patients assessed in the study. The
Cox hazard model also corroborated that these markers
encompassed prognostic factors for a lower death risk.
Patient survival analysis stratified by EGFR mutational
status combined with CEA and sEGFR marker levels
The mutational EGFR status together with the serum
CEA and sEGFR marker levels were assayed together in
order to quantify a better survival prediction (Table 6). It
was possible to only assay pair combinations in relation
to survival and risk owing to the low patient number re-
cording simultaneously data with respect to these three
variables when all of the three markers bore positive
states (mutated EGFR, sEGFR and CEA levels above of
the cut-off values; 3 patients) or negative (2 patients).
Only the EGFR mutational status and the sEGFR
level associated together significantly with a longer
progression-free survival (PFS) embracing a median of
23.5 months when the EGFR gene was mutated and the
protein serum levels displayed increased values, com-
pared to the 3.5 months in the case of patients with the
non-mutated gene also exhibiting inferior sEGFR levels
(p = 0.018) altogether enclosing a risk of progression of
4.37 (p = 0.026). Conversely, the EGFR mutation type
did not maintain a high significance with respect to the
PFS when combined with the CEA marker level, nor
did the combination of the high sEGFR and CEA levels
affect favourably the PFS.
On the contrary, concerning all three combinations
taken together better survival times were exhibited when
at least one of the markers had elevated levels or else
the EGFR gene was mutated, although in the case of the
sEGFR level and the EGFR gene mutational status the
significance threshold was not reached. The univariate
Cox analysis in relation to the overall-survival (OS) re-
vealed similar propensity-death hazard ratios in the caseEGFR mutation status analysed for survival
rvival Univariate cox analysis
CI) pb Progression Death
HR 95% CI p HR 95% CI p
21.1) 1.00 1.00
.6) 0.033 0.36 0.16 – 0.82 0.015 0.39 0.16 – 0.95 0.039
.4) 1.00 1.00
15.0) 0.004 0.55 0.2 – 1.5 0.243 0.21 0.07 – 0.7 0.008
.4) 1.00 1.00
2.9) 0.013 0.51 0.22 - 1.2 0.112 0.34 0.1 – 0.8 0.016
Table 6 Univariate analysis of the combination of EGFR mutational status, CEA and sEGFR for PFS and OS
Progression-free
survival
Overall survival Univariate cox analysis
Positive
markera
N Meb (95% CI) pc Meb (95% CI) pc Progression Death
HR 95% CI p HR 95% CI p
sEGFR +Mutation Status 2 5 23.5(−) 0.018 9.9(0.0 – 23.0) 0.067 1.000 1.000
1 14 7.0(4.9 – 9.0) 2.7(1.8 – 3.7) 2.497 0.782 – 7.979 0.123 4.050 0.904 – 18.148 0.068
0 9 3.5(0.1 – 6.9) 2.7(1.4 – 4.1) 4.370 1.195 – 15.986 0.026 7.894 1.607 – 38.775 0.011
CEA + Mutation Status 2 4 6.2(0.0 – 13.3) 0.338 6.5(0.6 – 12.5) 0.045 1.000 1.000
1 9 2.7(2.3 – 3.1) 10.2(2.8 – 17.6) 2.203 0.648 – 7.717 0.203 1.267 0.324 – 4.953 0.733
0 7 3.5(2.6 – 4.3) 5.0(1.0 – 9.1) 2.508 0.660 – 9.526 0.177 4.393 1.000 – 19.297 0.050
CEA + sEGFR Patients with
known mutation status
2 9 2.7(2.6 – 2.8) 0.689 10.5(9.6 – 11.4) 0.028 1.000 1.000
1 8 3.1(0.03 – 6.2) 5.2(3.2 – 7.3) 1.422 0.486 – 4.158 0.520 2.568 0.833 – 7.920 0.101
0 3 3.5(2.0 – 5.0) 4.2(3.0 – 5.4) 1.787 0.426 – 7.491 0.427 7.433 1.448 – 38.170 0.016
CEA + sEGFR all patients 2 14 3.2(0.0 – 7.2) 0.229 12.6(5.7 – 19.4) 0.003 1.000 1.000
1 16 2.6(1.9 – 3.4) 5.2(2.4 – 8.0) 1.931 0.840 – 7.305 0.121 2.962 1.170 – 7.496 0.022
0 4 2.5(1.4 – 3.7) 3.5(1.6 – 5.3) 2.192 0.658 – 7.305 0.201 8.359 2.111 – 33.095 0.002
Abbreviations: Me Median, HR Hazard Ratio, CI Confidence interval.
a(2) both markers positive (above the cut-off point or mutated EGFR), (1) only one positive and (0) both negative (below the cut-off point or WT EGFR); bMonths; cp value
calculated using the Log-Rank test.
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mutated EGFR genotype or low CEA levels, 7.89 (p = 0.011)
and 7.43 (p = 0.016) respectively. The combination of the
low CEA levels together with the non-mutated EGFR status
implied an increased death risk of 4.39 (p = 0.050).
Figure 1 presents according to the combination of the
sEGFR and CEA serum marker levels in conjunction
with the EGFR mutational gene status the Kaplan Meier
curves of the progression-free survival (PFS) and of the
overall survival (OS).Progression-free survival and overall survival multivariate
analysis
A multivariate Cox analysis was performed in order to
assess which variables would be independent survival
predictors of erlotinib treated NSCLC patients (Table 7).
Data regarding Performance status (PS) and CEA serum
marker levels were excluded from the multivariate
model, thus remaining a total of 25 patients for further
analysis.
Patients with mutated EGFR genotypes, sEGFR serum
marker levels above of the cut-off value of 56.87 ng/mL
and displaying toxicity symptoms presented diminished
progression and death risks compared to the patients
who exhibited the opposed characteristics. Nevertheless,
only sEGFR serum marker levels and erlotinib toxicity
resulted significant independent predictors of overall
survival (OS), whereas only the erlotinib toxicity was
also significant in the case of the progression-free sur-
vival (PFS).The death risk of patients with elevated sEGFR serum
marker levels comprised 0.27 (p = 0.013). Furthermore,
patients suffering from erlotinib toxicity exhibited a
much better prognosis, with poor progression (HR = 0.201,
p = 0.030) and death (HR = 0.088, p = 0.002) risks.Discussion
Serum biomarkers to predict the survival of NSCLC pa-
tients treated with erlotinib (Tarceva®) were investigated in
this study. Dating back to the development of the EURTAC
(Rosell et al. 2012) and OPTIMAL studies (Zhou et al.
2011), the EGFR gene mutation status has been widely
applied to select patients most likely to respond to the
EGFR-TKI treatments. Nonetheless, it needs to be indicated
that not all patients carrying EGFR gene mutations re-
spond receptively to EGFR-TKI treatments (Mitsudomi
et al. 2010; Tamura et al. 2008; Maemondo et al. 2010)
and also, on the other hand, that no mutations are
identified in 10-20% of patients with partial responses
to EGFR-TKIs (Pao et al. 2004; Lynch et al. 2004; Cappuzzo
et al. 2005; Bell et al. 2005; Han et al. 2005). Therefore,
the quest of different sensitivity prediction methods to
TKI based therapy in lung cancer remains an issue of
interest.
In this study we have tested in pre-treatment serum
several markers − such as sEGFR together with its asso-
ciated ligands TGF-α, EGF and HB-EGF − in relationship
to survival of NSCLC patients treated with the EGFR-
TKI erlotinib. Routine clinical markers were also assessed:
CEA, CYFRA 21–1 and SCC.
Figure 1 PFS and OS according to combination of sEGFR and CEA concentrations and EGFR mutational status. Groups consisted of the following:
(0) patients with sEGFR levels < 56.87 ng/mL or CEA < 5 ng/mL and a negative EGFR gene mutational status, (1) only one positive marker, (2)
patients with sEGFR > 56.87 ng/mL or CEA > 5 ng/mL and a positive EGFR gene mutational status. (A) and (B) Kaplan-Meier curves respectively of
PFS and OS according to the combination of the sEGFR serum marker levels and the EGFR gene mutational status. PFS (C) and OS (D) curves in
relation to the combination of the CEA serum levels and the EGFR gene mutational status. PFS (E) and OS (F) curves corresponding to the combination of
the CEA and sEGFR serum marker levels.
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sion free-survival-PFS outcomes are coincident to those
described in the main erlotinib drug evaluation studies
(Shepherd et al. 2005). The Kaplan-Meier analysis re-
vealed that only the performance status-PS, tumour hist-
ology and toxicity had a substantial impact on the OS ofthe erlotinib treated patients. The univariate analysis
corroborated that PS 2–3 in addition to no toxicity de-
velopment were significantly associated with a poor
prognosis. In coincidence with other previous studies
(Petrelli et al. 2012; Emery et al. 2009), toxicity has rep-
resented a protection factor indicative of a good clinical
Table 7 Multivariate models corresponding to progression-free survival and overall survival
Progression-free survival Overall survival
HR 95% CI pa HR 95% CI pa
sEGFR
<56.87 1.000 1.000
≥56.87 0.406 0.151 – 1.089 0.073 0.271 0.096 – 0.760 0.013
Mutational status
Wild type 1.000 1.000
EGFR Mutated 0.716 0.218 – 2.354 0.583 0.726 0.196 – 2.696 0.633
Toxicity
No 1.000 1.000
Yes 0.201 0.047 – 0.854 0.030 0.088 0.018 – 0.425 0.002
Abbreviations: HR Hazard Ratio, CI Confidence interval.
aWald test is used to calculate HR.
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results are also in line with those of preceding works
(Tsao et al. 2011; Jung et al. 2012).
In our study patients with pre-treatment sEGFR levels
higher than 56.87 ng/mL evidenced longer progression
free-survival (PFS) while especially overall survival (OS)
phases compared to patients containing lower serum
levels. Previously, Gregorc et al. (2004) and also Kappers
et al. (2010) had already obtained similar results observ-
ing that patients embracing higher pre-treatment sEGFR
serum levels were more likely to respond receptively.
Nonetheless, other authors have described the opposite
scenario disclosing discrepant sEGFR levels compared to
most of the information available (Kasahara et al. 2010;
Lemos-González et al. 2007), probably owing to the dif-
ferent methodology employed.
Of the different EGFR-specific ligands tested, none
showed a significant association with patient survival. In
the case of the serum marker HB-EGF a cut-off value
equal to 171.07 pg/mL separated those patients compris-
ing higher levels while presenting more extended pro-
gression free-survival-PFS and overall survival-OS episodes,
although statistical significance was not reached. These re-
sults are in direct contradiction to those of other authors
who have described high TGF-α and HB-EGF levels to be
associated with a progressive disease and a shorter overall
survival-OS lapse after NSCLC patients had been treated
with gefitinib (Masago et al. 2008).
Among the diverse clinical markers analysed in our
study, only the serum marker CEA revealed a statistical
significant relation with the treated patients’ survival.
Our finding establishing that high CEA levels consti-
tuted good predictors of survival regardless of the hist-
ology was a highly surprising and unexpected fact, as
previously in other studies regarding patients with more
advanced cancer stages who had been receiving chemo-
therapy these had displayed high CEA levels which had
been associated with a poor prognosis (Lin et al. 2012).Nevertheless, other authors have made similar observa-
tions to ours in advanced NSCLC patients undergoing
TKI based treatments (Jung et al. 2012; Okamoto et al.
2005). In the first study (Jung et al. 2012), high pre-
treatment CEA levels were significantly associated with
longer progression-free survival interludes. Similarly,
Okamoto et al. (2005) reported that EGFR TKI treated
patients with high pre-treatment CEA levels bestowed
longer survival terms and displayed better responses
than those patients encompassing lower CEA levels.
In relation to the serum marker CYFRA 21–1, levels
above of the cut-off limit showed lower overall survival-
OS rates, although the statistical significance threshold
was not surpassed. These results are very similar to those
described by Chen et al. (2010), who determined that this
marker’s pre-treatment levels might provide prognostic in-
formation in the case of gefitinib treatments.
So far few reports exist regarding the relationship be-
tween serological marker levels and the curative effect of
erlotinib. The associated shortcomings of these studies
include an EGFR mutation test lack, the very low patient
number (Ishikawa et al. 2005), or else only wild-type pa-
tient analysis (Chang et al. 2011).
We have included in our study data pertaining to the
EGFR mutational status of 32 characterised patients
(tumour tissue was not available for the remaining sub-
jects). Mutations were detected among 11 patients with
a resulting EGFR gene mutation rate of 34%. This per-
centage is markedly superior to the EGFR gene mutation
frequency reported for European Caucasians covering
9.8% in the case of German NSCLC patients (Gahr et al.
2013) and amounting to 16.6% with respect to a Spanish
population of advanced NSCLC patients (Rosell et al.
2009). The EGFR gene mutation frequency discrepancies
are best explained on the basis of the selection criteria
employed in this study restricting the eligible NSCLC
patients to those receiving an erlotinib treatment, in spite
of including all of the NSCLC patients, together with
Romero-Ventosa et al. SpringerPlus  (2015) 4:171 Page 9 of 13some patient’s non-availability of tumour tissue which
precluded an accurate EGFR gene mutation estimate.
Our results related to the EGFR mutational status indi-
cated a strong association (Fisher analysis close to signifi-
cance) between the EGFR mutations present and the
response to the erlotinib treatment. Furthermore, the
mutational status holds a prognostic value as the mutated
EGFR gene patients displayed higher overall-survival (OS)
and progression free-survival (PFS) episodes in compari-
son to patients lacking mutations, also corroborated by
the univariate Cox analysis which revealed that progres-
sion and death are less prone to occur in patients bearing
mutations. Our data agrees with that of previous studies
(Inoue et al. 2006; Rosell et al. 2012; Tamura et al. 2008;
Sequist et al. 2008).
As was also observed in the case of Chang et al.
(2011), some patients responded positively to erlotinib
medication although they presented the wild type EGFR
genotype: 4.8% manifested partial responses (PR), 57.1%
exhibited stable disease development (SD) while 33.3%
incurred in disease progression (PD).
Death predictive markers disclosed by the univariate
analysis, the EGFR gene mutational status in addition to
the serum CEA and sEGFR marker levels, were further
assayed in combination in order to assess better survival
predictions. Marker combinations were evaluated among
three categories: (2) both positive markers (above of the
cut-off threshold or else a mutated EGFR genotype), (1)
only one marker positive and (0) both markers negative
(below of the cut-off threshold or else a wild type EGFR
genotype). The combination of the sEGFR level together
with the EGFR gene mutational status did not have a
significant impact on the overall survival (OS) as re-
vealed by the Kaplan-Meier analysis, even though the
median survival time was the highest for elevated sEGFR
levels and mutated EGFR genes, while the Cox analysis
indicated that possessing wild type EGFR tumours to-
gether with low receptor levels present in the pre-
treatment serum entailed a death risk factor, holding
those patients a hazard ratio (HR) 7.89 times higher in
contrast to patients with tumours bearing a mutated
EGFR gene and expressing high sEGFR levels. Accordingly,
we do not consider the sEGFR level in conjunction with
the EGFR gene mutational status a worthy combination.
Noticeably, sEGFR and CEA levels combined together
significantly determined overall survival (OS), thus hav-
ing represented a more useful combination that achieves
longer survival in erlotinib-treated patients. Combined
high pre-treatment serum CEA and sEGFR levels clearly
indicated a better prognosis granted that these patients
showed higher OS (12.6 months) time frames weighed
against those individuals displaying only one marker
with an elevated level (5.2 months), whilst particularly in
contrast to those patients with both markers expressinglow levels (3.5 months), all confirmed by the Cox ana-
lysis disclosing that group 0 patients sustained a hazard
ratio (HR) 8.36 times higher than that of the group 2 pa-
tients. Almost the same results could be observed when
only the patients with a known mutational status were
considered. Compared to the single EGFR mutational
status determination, it remains worthy to highlight that
the combined CEA and sEGFR use allowed to discern
14 patients (41%) with a prolonged OS, whereas the
mutational status analysis permitted to distinguish 11
patients (34.3%); moreover, the OS benefit of both the
positive sEGFR and CEA levels combined was at least as
good as the survival increase of patients with the mu-
tated EGFR gene, in both cases spanning 12.6 months.
Nonetheless, it should be kept in mind that the prognos-
tic value incremental evaluation of the sEGFR and CEA
levels combined to that of the EGFR gene mutational
status standing alone was not performed due to insuffi-
cient available data, as has already been explained else-
where. The before mentioned results suggest that the
combined CEA and sEGFR usage may provide an
equivalent prognostic information to that of the EGFR
gene mutational status with regard to determining
NSCLC erlotinib treated patient prognosis.
Using a multivariate Cox regression model only the
pre-treatment sEGFR level together with erlotinib tox-
icity remained significant survival predictors. Although
all of the variables with a significant death risk impact
should have been included in the univariate analysis:
performance status (PS), erlotinib toxicity, EGFR gene
mutational status and pre-treatment serum levels of the
sEGFR and CEA markers, we could not include in the
multivariate analysis the marker CEA or the perform-
ance status due to an insufficient amount of data.
Reinforcing our results, Gregorc et al. (2004) had previ-
ously studied the sEGFR levels of patients with advanced
NSCLC stages observing that high sEGFR levels were
significant with respect to the three multivariate analyses
performed.
Our study presents some weaknesses; in this line our
main concern contemplates the limited number of re-
cruited individuals owing to the peculiarities of the selected
subjects, in addition to an insufficient serum volume, which
precluded the whole population determination of all of the
markers. In the future, larger studies to corroborate the
preliminary prognosis conclusions of the erlotinib-treated
patients based on combined sEGFR and CEA data are
needed that, in addition, could also confirm the potential of
other biomarkers that might have been underestimated,
such as could be the case of the HB-EGF and CYFRA 21.1
serum markers, whose levels showed survival and risk
relations close to significance. Despite of these short-
comings, the high CEA and sEGFR prognostic value
similarity displayed for the whole population survival
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EGFR gene mutational status indicates that the limited
sample size has not affected the results.
Secondly, as our patient cohort was heterogeneous in
relation to the previous treatment, caution should be
exercised in drawing any firm conclusions. Our analyses
have all been based on erlotinib-treated patient out-
comes, given that our study lacked a control group (pa-
tients who had not received erlotinib treatment), thus,
results do not allow to differentiate whether the survival
benefit was due to a prognostic or predictive value of
the serum markers sEGFR and CEA to identify patients
who would respond positively to erlotinib therapy (Coate
et al. 2009).
Conclusions
The present study has indicated that pre-treatment
levels above 5 ng/mL of CEA or above 56.87 ng/mL of
sEGFR comprise survival markers designed for NSCLC
patients treated with erlotinib. The combined assess-
ment of sEGFR and CEA serum marker levels could be
of value in order to pre-select patients to undergo
EGFR-TKI treatments. This is in particular relevant in
circumstances when tumour tissues are insufficient or
else the hospital lacks the appropriate facilities, in view
of the fact that sEGFR and CEA level determinations are
routinely feasible whilst relatively non-invasive and inex-
pensive procedures.
Methods
Patients and treatment assessment response
A total of 58 patients were included in this study diagnosed
with NSCLC who had been treated with the TKI erlotinib
at the Complejo Hospitalario Universitario de Vigo (Spain)
from July 2009 to June 2011. The inclusion criterion com-
prised all patients who had received erlotinib medication
during the study period as first or second-line treatment,
these patients had failed to respond to conventional intra-
venous chemotherapy or had been unable to receive
chemotherapy. Patients were treated with daily doses of
150 mg and dose reductions of 50 mg were undertaken in
cases of observing unacceptable toxicity.
Performance status (PS) and the treatments received
prior to the erlotinib therapy were recorded. PS refers to
the manner in which the patient’s disease progresses
affecting the daily vital capabilities, thus being applied to
determine an appropriate treatment and prognosis. PS
data was collected following the Eastern Cooperative On-
cology Group scale (Oken et al. 1982). Erlotinib-derived
toxicity data was also collected denoting any toxicity type
experienced by patients due to the treatment received.
The objective tumour response was assessed every
3 months after the beginning of the treatment by means
of a computerized tomography according to the ResponseEvaluation Criteria of Solid Tumors (Eisenhauer et al.
2009). Each patient’s response was then classified into
one of the following categories: responders, including
cases of complete response (CR), partial response (PR)
and stable disease development (SD); and non responders,
including cases of disease progression (PD).
All of the patients provided an informed consent be-
fore of the enrolment in the study and marker determin-
ation was accomplished without interrupting the normal
clinical practices. The study followed all of the guidelines
set up to undertake experimental investigation as required
by the authors’ institutions and complied fully with the
Helsinki Declaration.
Serum marker level determinations
Blood samples were collected before of the EGFR-TKI treat-
ment initiation. Separated serums were stored at −25°C until
further use.
CEA and CYFRA 21–1 measurements were carried out
by electrochemiluminescence immunoassays (ECLIA, Roche
Diagnostics, Germany) using an Elecsys® 2010 analyzer. The
SCC antigen determination was accomplished by means of
the TRACE technology (Time-Resolved Amplified Cryptate
Emission) making use of a KRIPTOR BRAHMS-ATOM®
apparatus.
The DuoSet® ELISA Development System human (R&D
Systems Minneapolis, MN) kits were used in order to de-
termine the sEGFR, EGF, HB-EGF and TGF-α concentra-
tions present in the serums, performed according to
manufacturer’s instructions. Optical densities were read
by way of an EnVision Multilabel Plate Reader (Perkin
Elmer). Final sample sizes to determine marker concentra-
tions depended on the patient’s available serum quantities.
EGFR gene mutation analysis
Tumour tissue samples for EGFR mutation testing were
available only for 33 patients (12 women, 20 men, one
patient was excluded due to an unspecified mutation type).
The Cobas EGFR Mutation Test kit (Roche Molecular Sys-
tems, Inc., Branchburg, USA) entailing a CE-IVD-marked
allele-specific PCR test designed to detect the presence of
41 mutations within exons 18, 19, 20 and 21 of the TK do-
main was applied to paraffin-embedded tissue blocks. Data
analysis and interpretation was implemented through the
computer software Cobas z 480 (Roche Molecular Systems,
Inc., Branchburg, USA).
Statistical analysis
Normality of the continuous variable distributions was
assessed using the Kolmogorov-Smirnov test. Variable dis-
tribution differences between and among groups regard-
ing the EGFR mutational status were compared using
Fisher’s exact test. Receiver operating characteristic curves
Romero-Ventosa et al. SpringerPlus  (2015) 4:171 Page 11 of 13(ROC) were drawn for the novel tumour markers (sEGFR,
EGF, HB-EGF and TGF-α) in order to assess their discern-
ing value to tell apart the non-progressive from progres-
sive patients and also to establish the survival analysis cut-
off values: 56.87 ng/mL in the case of sEGFR, 713.59 pg/
mL with respect to EGF, 171.07 pg/mL regarding HB-EGF
and 21.81 pg/mL concerning TGF-α. The pertinent cut-
off values of CEA, CYFRA 21–1 and SCC were respect-
ively established at 5 ng/mL, 3.3 ng/mL and 1.5 ng/mL.
The progression-free survival (PFS), the overall sur-
vival (OS) and the 95% confidence intervals (95% CI)
were assessed through the Kaplan-Meier method while
survival differences between patients’ groups were com-
pared by means of the Log-Rank test. PFS values were
calculated starting the date of erlotinib treatment initi-
ation up to the date of the first PD appearance or else
up to the date of the last contact. The OS values were
estimated from the date of therapy initiation up to the
death date arising from any cause or else up to the date
of the last contact. The association of risk factors with
survival was evaluated according to the Cox propor-
tional hazards regression model. The multivariate ana-
lysis was performed using a logistic regression model in
order to identify those variables associating independ-
ently with survival. Statistical significances were defined
at the p < 0.05 probability level. The statistical analysis
was carried out using the software package SPSS V15
run under Windows (Copyright© SPSS Inc. 1989–2002,
Chicago, IL).
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